MALAT1 and metabolic dysfunction-associated steatotic liver disease: Although the role of MALAT1 and the impact of GLP-1RAs in steatosis have not yet been examined in vivo, there is substantial evidence supporting their ability to reduce the liver fat content in both animal models and patients with NAFLD.